Harry H. Yoon, MD
Following the FDA approval of the PD-1 inhibitor pembrolizumab (Keytruda) in September, the field of gastric cancer and gastroesophageal junction (GEJ) adenocarcinoma is buzzing when it comes to immunotherapies.
on Gastrointestinal Cancers, Yoon proposed the use of PD-1 inhibitors in earlier lines of therapy. In an interview at the meeting, Yoon discussed the promise of immunotherapy and emphasized the importance of mismatch repair (MMR) deficiency testing.
OncLive: Please provide an overview of your discussion on gastric cancer.
I spoke about the most updated information that affects our standard practice, and what the most promising developments are on the horizon for gastric cancer.
... to read the full story